PRO DEX INC
Pro-Dex designs, develops and manufactures autoclavable, battery-powered and electric, multi-function surgical drivers and shavers, primarily for orthopedic, thoracic and craniomaxillofacial markets. Its customers are primarily medical device distributors and original equipment manufacturers. The company also provides engineering, quality and regulatory consulting, non-recurring engineering and prototype services, and repairs. It earns money mainly by designing and manufacturing medical devices and by repairing them, including products developed under customer agreements or manufactured to customer designs. Pro-Dex also sells rotary air motors to distributors and end users, and precision-machined parts and assemblies for the medical, aerospace and defense industries through subsidiary Advanced Precision Machining. Pro-Dex operates one business segment. Its medical device products are machined at its Irvine facility and assembled in Tustin, California. Advanced Precision Machining operates in Costa Mesa, California and also serves as a Prime Contractor for the U.S. Government. Pro-Dex is headquartered in Irvine, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $PDEX in the last 7 days.
No SEC Form 4 filings for $PDEX in the last 30 days.
See all $PDEX insider activity →PRO DEX INC (PDEX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 26, 2026, Advanced Precision Machining, LLC (“APM”), a wholly owned subsidiary of Pro-Dex, Inc. (the “Company”), entered into three Standard Lease Renewal Forms (the “Lease Renewals”) with Trico Costa Mesa Propertie
Pro-Dex reported Q1 GAAP EPS of $0.92, exceeding estimates by $0.25. Revenue was $20.6M, up 11.2% year-over-year and $0.2M above expectations. The company's financial performance is relevant for investors tracking its stock.
PRO DEX INC (PDEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2027 FIRST QUARTER RESULTS IRVINE, CA, October 29, 2026 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2027 fi
Recent PDEX coverage spans earnings, corporate actions and insider activity.
Higher operating costs may weigh on margins.
Beat on both EPS and revenue suggests near-term upside bias, but the article provides no guidance or margin detail to confirm durability.
Earnings miss on profit may pressure the stock despite top‑line growth.
Positive earnings surprise may lift the stock, but concentration risk on a single customer could limit upside.
The lease amendment has minimal immediate impact on valuation; it secures occupancy but adds modest rent expense.
AlphAI scores every news story that mentions PDEX with an AI model for sentiment and relevance, and aggregates insider trades from PRO DEX INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
PRO DEX INC (PDEX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 26, 2026, Advanced Precision Machining, LLC (“APM”), a wholly owned subsidiary of Pro-Dex, Inc. (the “Company”), entered into three Standard Lease Renewal Forms (the “Lease Renewals”) with Trico Costa Mesa Propertie
Pro-Dex reported Q1 GAAP EPS of $0.92, exceeding estimates by $0.25. Revenue was $20.6M, up 11.2% year-over-year and $0.2M above expectations. The company's financial performance is relevant for investors tracking its stock.
PRO DEX INC (PDEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2027 FIRST QUARTER RESULTS IRVINE, CA, October 29, 2026 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2027 fi
Pro-Dex (PDEX) reported fiscal 2026 net sales of $77.55M, up 16%, and net income of $13.66M, up 52%. Medical-device sales rose 30%, while repair revenue fell 33%. The largest customer accounted for 78% of sales with a supply agreement through 2028. Operating cash flow was $7.24M, and the company repurchased 79,898 shares.
PRO DEX INC (PDEX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 16, 2026, Pro-Dex, Inc. (the “Company”) entered into a Third Amendment to Standard Industrial/Commercial Multi-Tenant Lease – Net (the “Third Amendment”) with Irvine Business Properties, a California general partn
Van Kirk Richard Lee Jr (Chief Executive Officer) sold 19,235 shares of PRO DEX INC (PDEX) at an average of $60.58 ($58.66–$64.70, $1.17M total) across 9 trades on 2026-09-09 under a Rule 10b5-1 trading plan.
Charlton Alisha (Chief Financial Officer) sold 2,300 shares of PRO DEX INC (PDEX) at an average of $61.30 ($61.05–$61.76, $0.14M total) across 2 trades on 2026-09-09.
Pro-Dex (PDEX) rose 18% to $77 on FY'26 results, with net sales up 16% to $77.5M. Odyssey (ODTX) gained 8% to $29.05, reporting a Q2 loss of $52.8M. Evolus (EOLS) climbed 2% to $9.31, with Q2 revenue up 21% to $84.1M. Biofrontera (BFRI) increased 6% to $1.63, with Q2 product revenue up 32.9%. Alpha Tau (DRTS) hit $15.17, reporting a Q2 loss of $68.8M.
Pro-Dex (PDEX) reported strong fiscal 2026 results with 17% Q4 sales growth and 16% annual sales increase. Modular Medical (MODD) gained FDA clearance for Pivot pump software. ENvue Medical (FEED) selected for Vizient Innovative Technology Exchange. Attovia (ATTO) and Pyxis Oncology (PYXS) provided clinical updates and financials. All stocks rose Friday.
Modular Medical (MODD) received FDA clearance for software enhancements to its Pivot insulin pump, planning a commercial launch in October 2026. Galmed (GLMD) shareholders approved all proposals, including a name change. Pro-Dex (PDEX) reported strong Q4 results with 17% sales growth. eHealth (EHTH) saw after-hours gains despite a Q2 net loss. Connect Biopharma (CNTB) will present at a conference and report Phase 2 trial results. AVITA Medical (RCEL) expects full-year revenue of $86M-$89M.
